Pink Sheets Filings Reply To Shareholders FAQ on Various Past News and General Corporate Update
SHENZHEN, China, Oct. 1 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) The issuer's China based operating subsidiary Mellow Hope and Serbia operating Subsidiary Slavica Bio Chem are providing news release to bring attention to today's Pink Sheets filing. The filing found on Pink Sheets HTDS listing or this link http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds
The company hopes that this filing bring its followers and shareholders up to date with various events and pending transactions, and to provide an update on past news releases. The filing is intensive 4 pages covering short sellers, naked short positions. The superficial "skull and bones" icon effecting HTDS, IP rights, cancer project and unsolicited buyer, H1N1 business and pending foreign defamation judgment and other FAQ topics of HTDS followers and shareholders.
The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 1:30pm EST.
To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact email@example.com; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)
SOURCE Hard to Treat Diseases
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved